The fight against curing Alzheimer's has made a huge milestone after a new drug reduced memory decline among patients.
Lecanemab was designed to target and clear amyloid - one of the proteins that build up in the brains of people with Alzheimer's. Experts are hailing the treatment as the "beginning of the end" in searching for effective treatment for the illness.
Phase three clinical trial results were reported by Eisai, a Tokyo-based pharmaceutical company that partnered with US biotech firm Biogen to develop lecanemab. Eisai reported initial results in September from a trial involving 1,795 participants with early Alzheimer's disease.
